nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—Anxiety—Dexamethasone—psoriasis	0.00012	0.00012	CcSEcCtD
Pramipexole—Anxiety—Betamethasone—psoriasis	0.00012	0.00012	CcSEcCtD
Pramipexole—Vomiting—Mycophenolic acid—psoriasis	0.000119	0.00012	CcSEcCtD
Pramipexole—Discomfort—Betamethasone—psoriasis	0.000119	0.000119	CcSEcCtD
Pramipexole—Discomfort—Dexamethasone—psoriasis	0.000119	0.000119	CcSEcCtD
Pramipexole—Dyspepsia—Hydrocortisone—psoriasis	0.000119	0.000119	CcSEcCtD
Pramipexole—Rash—Mycophenolic acid—psoriasis	0.000118	0.000119	CcSEcCtD
Pramipexole—Dermatitis—Mycophenolic acid—psoriasis	0.000118	0.000119	CcSEcCtD
Pramipexole—Pain—Prednisolone—psoriasis	0.000118	0.000118	CcSEcCtD
Pramipexole—Urticaria—Mycophenolate mofetil—psoriasis	0.000118	0.000118	CcSEcCtD
Pramipexole—Headache—Mycophenolic acid—psoriasis	0.000117	0.000118	CcSEcCtD
Pramipexole—Decreased appetite—Hydrocortisone—psoriasis	0.000117	0.000118	CcSEcCtD
Pramipexole—Pharyngitis—Methotrexate—psoriasis	0.000117	0.000118	CcSEcCtD
Pramipexole—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000117	0.000117	CcSEcCtD
Pramipexole—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000117	0.000117	CcSEcCtD
Pramipexole—Urinary tract disorder—Methotrexate—psoriasis	0.000117	0.000117	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000116	0.000117	CcSEcCtD
Pramipexole—Fatigue—Hydrocortisone—psoriasis	0.000116	0.000117	CcSEcCtD
Pramipexole—Vision blurred—Prednisone—psoriasis	0.000116	0.000116	CcSEcCtD
Pramipexole—Urethral disorder—Methotrexate—psoriasis	0.000116	0.000116	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000116	0.000116	CcSEcCtD
Pramipexole—Pain—Hydrocortisone—psoriasis	0.000115	0.000116	CcSEcCtD
Pramipexole—Oedema—Betamethasone—psoriasis	0.000115	0.000116	CcSEcCtD
Pramipexole—Oedema—Dexamethasone—psoriasis	0.000115	0.000116	CcSEcCtD
Pramipexole—Insomnia—Triamcinolone—psoriasis	0.000115	0.000115	CcSEcCtD
Pramipexole—Infection—Dexamethasone—psoriasis	0.000114	0.000115	CcSEcCtD
Pramipexole—Infection—Betamethasone—psoriasis	0.000114	0.000115	CcSEcCtD
Pramipexole—Ill-defined disorder—Prednisone—psoriasis	0.000114	0.000114	CcSEcCtD
Pramipexole—Paraesthesia—Triamcinolone—psoriasis	0.000114	0.000114	CcSEcCtD
Pramipexole—Feeling abnormal—Prednisolone—psoriasis	0.000114	0.000114	CcSEcCtD
Pramipexole—Visual impairment—Methotrexate—psoriasis	0.000114	0.000114	CcSEcCtD
Pramipexole—Anaemia—Prednisone—psoriasis	0.000114	0.000114	CcSEcCtD
Pramipexole—Shock—Dexamethasone—psoriasis	0.000113	0.000114	CcSEcCtD
Pramipexole—Shock—Betamethasone—psoriasis	0.000113	0.000114	CcSEcCtD
Pramipexole—Dyspnoea—Triamcinolone—psoriasis	0.000113	0.000114	CcSEcCtD
Pramipexole—Nervous system disorder—Dexamethasone—psoriasis	0.000113	0.000113	CcSEcCtD
Pramipexole—Nervous system disorder—Betamethasone—psoriasis	0.000113	0.000113	CcSEcCtD
Pramipexole—Agitation—Prednisone—psoriasis	0.000113	0.000113	CcSEcCtD
Pramipexole—Thrombocytopenia—Betamethasone—psoriasis	0.000113	0.000113	CcSEcCtD
Pramipexole—Thrombocytopenia—Dexamethasone—psoriasis	0.000113	0.000113	CcSEcCtD
Pramipexole—Tachycardia—Betamethasone—psoriasis	0.000112	0.000113	CcSEcCtD
Pramipexole—Tachycardia—Dexamethasone—psoriasis	0.000112	0.000113	CcSEcCtD
Pramipexole—Hypersensitivity—Cyclosporine—psoriasis	0.000112	0.000112	CcSEcCtD
Pramipexole—Dyspepsia—Triamcinolone—psoriasis	0.000112	0.000112	CcSEcCtD
Pramipexole—Nausea—Mycophenolic acid—psoriasis	0.000111	0.000112	CcSEcCtD
Pramipexole—Hyperhidrosis—Betamethasone—psoriasis	0.000111	0.000112	CcSEcCtD
Pramipexole—Hyperhidrosis—Dexamethasone—psoriasis	0.000111	0.000112	CcSEcCtD
Pramipexole—Feeling abnormal—Hydrocortisone—psoriasis	0.000111	0.000111	CcSEcCtD
Pramipexole—Malaise—Prednisone—psoriasis	0.000111	0.000111	CcSEcCtD
Pramipexole—Vertigo—Prednisone—psoriasis	0.00011	0.000111	CcSEcCtD
Pramipexole—Eye disorder—Methotrexate—psoriasis	0.00011	0.000111	CcSEcCtD
Pramipexole—Gastrointestinal pain—Hydrocortisone—psoriasis	0.00011	0.000111	CcSEcCtD
Pramipexole—Syncope—Prednisone—psoriasis	0.00011	0.000111	CcSEcCtD
Pramipexole—Tinnitus—Methotrexate—psoriasis	0.00011	0.00011	CcSEcCtD
Pramipexole—Anorexia—Dexamethasone—psoriasis	0.00011	0.00011	CcSEcCtD
Pramipexole—Anorexia—Betamethasone—psoriasis	0.00011	0.00011	CcSEcCtD
Pramipexole—Urticaria—Prednisolone—psoriasis	0.00011	0.00011	CcSEcCtD
Pramipexole—Cardiac disorder—Methotrexate—psoriasis	0.00011	0.00011	CcSEcCtD
Pramipexole—Fatigue—Triamcinolone—psoriasis	0.000109	0.00011	CcSEcCtD
Pramipexole—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000109	0.000109	CcSEcCtD
Pramipexole—Asthenia—Cyclosporine—psoriasis	0.000109	0.000109	CcSEcCtD
Pramipexole—Pain—Triamcinolone—psoriasis	0.000109	0.000109	CcSEcCtD
Pramipexole—Loss of consciousness—Prednisone—psoriasis	0.000108	0.000108	CcSEcCtD
Pramipexole—Hypotension—Betamethasone—psoriasis	0.000108	0.000108	CcSEcCtD
Pramipexole—Hypotension—Dexamethasone—psoriasis	0.000108	0.000108	CcSEcCtD
Pramipexole—Pruritus—Cyclosporine—psoriasis	0.000107	0.000108	CcSEcCtD
Pramipexole—Urticaria—Hydrocortisone—psoriasis	0.000107	0.000107	CcSEcCtD
Pramipexole—Angiopathy—Methotrexate—psoriasis	0.000107	0.000107	CcSEcCtD
Pramipexole—Immune system disorder—Methotrexate—psoriasis	0.000107	0.000107	CcSEcCtD
Pramipexole—Abdominal pain—Hydrocortisone—psoriasis	0.000107	0.000107	CcSEcCtD
Pramipexole—Body temperature increased—Hydrocortisone—psoriasis	0.000107	0.000107	CcSEcCtD
Pramipexole—Convulsion—Prednisone—psoriasis	0.000106	0.000107	CcSEcCtD
Pramipexole—Mediastinal disorder—Methotrexate—psoriasis	0.000106	0.000107	CcSEcCtD
Pramipexole—Asthenia—Mycophenolate mofetil—psoriasis	0.000106	0.000107	CcSEcCtD
Pramipexole—Hypertension—Prednisone—psoriasis	0.000106	0.000106	CcSEcCtD
Pramipexole—Chills—Methotrexate—psoriasis	0.000106	0.000106	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000105	0.000105	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000105	0.000105	CcSEcCtD
Pramipexole—Pruritus—Mycophenolate mofetil—psoriasis	0.000105	0.000105	CcSEcCtD
Pramipexole—Arthralgia—Prednisone—psoriasis	0.000105	0.000105	CcSEcCtD
Pramipexole—Myalgia—Prednisone—psoriasis	0.000105	0.000105	CcSEcCtD
Pramipexole—Feeling abnormal—Triamcinolone—psoriasis	0.000105	0.000105	CcSEcCtD
Pramipexole—Anxiety—Prednisone—psoriasis	0.000104	0.000105	CcSEcCtD
Pramipexole—Alopecia—Methotrexate—psoriasis	0.000104	0.000105	CcSEcCtD
Pramipexole—Insomnia—Dexamethasone—psoriasis	0.000104	0.000105	CcSEcCtD
Pramipexole—Insomnia—Betamethasone—psoriasis	0.000104	0.000105	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000104	0.000104	CcSEcCtD
Pramipexole—Diarrhoea—Cyclosporine—psoriasis	0.000104	0.000104	CcSEcCtD
Pramipexole—Paraesthesia—Dexamethasone—psoriasis	0.000103	0.000104	CcSEcCtD
Pramipexole—Paraesthesia—Betamethasone—psoriasis	0.000103	0.000104	CcSEcCtD
Pramipexole—Discomfort—Prednisone—psoriasis	0.000103	0.000104	CcSEcCtD
Pramipexole—Mental disorder—Methotrexate—psoriasis	0.000103	0.000104	CcSEcCtD
Pramipexole—Malnutrition—Methotrexate—psoriasis	0.000103	0.000103	CcSEcCtD
Pramipexole—Erythema—Methotrexate—psoriasis	0.000103	0.000103	CcSEcCtD
Pramipexole—Hypersensitivity—Prednisolone—psoriasis	0.000102	0.000102	CcSEcCtD
Pramipexole—Dyspepsia—Dexamethasone—psoriasis	0.000101	0.000102	CcSEcCtD
Pramipexole—Dyspepsia—Betamethasone—psoriasis	0.000101	0.000102	CcSEcCtD
Pramipexole—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000101	0.000102	CcSEcCtD
Pramipexole—Urticaria—Triamcinolone—psoriasis	0.000101	0.000101	CcSEcCtD
Pramipexole—Dysgeusia—Methotrexate—psoriasis	0.000101	0.000101	CcSEcCtD
Pramipexole—Body temperature increased—Triamcinolone—psoriasis	0.0001	0.000101	CcSEcCtD
Pramipexole—Dizziness—Cyclosporine—psoriasis	0.0001	0.000101	CcSEcCtD
Pramipexole—Oedema—Prednisone—psoriasis	0.0001	0.000101	CcSEcCtD
Pramipexole—Decreased appetite—Betamethasone—psoriasis	0.0001	0.0001	CcSEcCtD
Pramipexole—Decreased appetite—Dexamethasone—psoriasis	0.0001	0.0001	CcSEcCtD
Pramipexole—Infection—Prednisone—psoriasis	9.97e-05	0.0001	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Betamethasone—psoriasis	9.94e-05	9.98e-05	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Dexamethasone—psoriasis	9.94e-05	9.98e-05	CcSEcCtD
Pramipexole—Back pain—Methotrexate—psoriasis	9.94e-05	9.97e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Hydrocortisone—psoriasis	9.93e-05	9.97e-05	CcSEcCtD
Pramipexole—Fatigue—Dexamethasone—psoriasis	9.93e-05	9.96e-05	CcSEcCtD
Pramipexole—Fatigue—Betamethasone—psoriasis	9.93e-05	9.96e-05	CcSEcCtD
Pramipexole—Shock—Prednisone—psoriasis	9.87e-05	9.9e-05	CcSEcCtD
Pramipexole—Pain—Dexamethasone—psoriasis	9.85e-05	9.88e-05	CcSEcCtD
Pramipexole—Pain—Betamethasone—psoriasis	9.85e-05	9.88e-05	CcSEcCtD
Pramipexole—Nervous system disorder—Prednisone—psoriasis	9.84e-05	9.87e-05	CcSEcCtD
Pramipexole—Tachycardia—Prednisone—psoriasis	9.79e-05	9.82e-05	CcSEcCtD
Pramipexole—Dizziness—Mycophenolate mofetil—psoriasis	9.79e-05	9.82e-05	CcSEcCtD
Pramipexole—Skin disorder—Prednisone—psoriasis	9.74e-05	9.78e-05	CcSEcCtD
Pramipexole—Hyperhidrosis—Prednisone—psoriasis	9.7e-05	9.73e-05	CcSEcCtD
Pramipexole—Vision blurred—Methotrexate—psoriasis	9.68e-05	9.71e-05	CcSEcCtD
Pramipexole—Asthenia—Hydrocortisone—psoriasis	9.67e-05	9.71e-05	CcSEcCtD
Pramipexole—Vomiting—Cyclosporine—psoriasis	9.65e-05	9.68e-05	CcSEcCtD
Pramipexole—Rash—Cyclosporine—psoriasis	9.56e-05	9.6e-05	CcSEcCtD
Pramipexole—Anorexia—Prednisone—psoriasis	9.56e-05	9.59e-05	CcSEcCtD
Pramipexole—Dermatitis—Cyclosporine—psoriasis	9.56e-05	9.59e-05	CcSEcCtD
Pramipexole—Pruritus—Hydrocortisone—psoriasis	9.54e-05	9.57e-05	CcSEcCtD
Pramipexole—Ill-defined disorder—Methotrexate—psoriasis	9.53e-05	9.56e-05	CcSEcCtD
Pramipexole—Headache—Cyclosporine—psoriasis	9.5e-05	9.54e-05	CcSEcCtD
Pramipexole—Anaemia—Methotrexate—psoriasis	9.49e-05	9.53e-05	CcSEcCtD
Pramipexole—Feeling abnormal—Dexamethasone—psoriasis	9.49e-05	9.52e-05	CcSEcCtD
Pramipexole—Feeling abnormal—Betamethasone—psoriasis	9.49e-05	9.52e-05	CcSEcCtD
Pramipexole—Gastrointestinal pain—Dexamethasone—psoriasis	9.42e-05	9.45e-05	CcSEcCtD
Pramipexole—Gastrointestinal pain—Betamethasone—psoriasis	9.42e-05	9.45e-05	CcSEcCtD
Pramipexole—Vomiting—Mycophenolate mofetil—psoriasis	9.41e-05	9.44e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Triamcinolone—psoriasis	9.35e-05	9.38e-05	CcSEcCtD
Pramipexole—Rash—Mycophenolate mofetil—psoriasis	9.33e-05	9.36e-05	CcSEcCtD
Pramipexole—Dermatitis—Mycophenolate mofetil—psoriasis	9.32e-05	9.35e-05	CcSEcCtD
Pramipexole—Headache—Mycophenolate mofetil—psoriasis	9.27e-05	9.3e-05	CcSEcCtD
Pramipexole—Malaise—Methotrexate—psoriasis	9.26e-05	9.29e-05	CcSEcCtD
Pramipexole—Vertigo—Methotrexate—psoriasis	9.23e-05	9.26e-05	CcSEcCtD
Pramipexole—Diarrhoea—Hydrocortisone—psoriasis	9.22e-05	9.26e-05	CcSEcCtD
Pramipexole—Leukopenia—Methotrexate—psoriasis	9.19e-05	9.23e-05	CcSEcCtD
Pramipexole—Urticaria—Dexamethasone—psoriasis	9.15e-05	9.18e-05	CcSEcCtD
Pramipexole—Urticaria—Betamethasone—psoriasis	9.15e-05	9.18e-05	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Prednisone—psoriasis	9.14e-05	9.17e-05	CcSEcCtD
Pramipexole—Dizziness—Prednisolone—psoriasis	9.13e-05	9.16e-05	CcSEcCtD
Pramipexole—Asthenia—Triamcinolone—psoriasis	9.11e-05	9.14e-05	CcSEcCtD
Pramipexole—Abdominal pain—Dexamethasone—psoriasis	9.11e-05	9.14e-05	CcSEcCtD
Pramipexole—Body temperature increased—Betamethasone—psoriasis	9.11e-05	9.14e-05	CcSEcCtD
Pramipexole—Body temperature increased—Dexamethasone—psoriasis	9.11e-05	9.14e-05	CcSEcCtD
Pramipexole—Abdominal pain—Betamethasone—psoriasis	9.11e-05	9.14e-05	CcSEcCtD
Pramipexole—Insomnia—Prednisone—psoriasis	9.07e-05	9.1e-05	CcSEcCtD
Pramipexole—Nausea—Cyclosporine—psoriasis	9.01e-05	9.04e-05	CcSEcCtD
Pramipexole—Paraesthesia—Prednisone—psoriasis	9.01e-05	9.04e-05	CcSEcCtD
Pramipexole—Pruritus—Triamcinolone—psoriasis	8.98e-05	9.01e-05	CcSEcCtD
Pramipexole—Cough—Methotrexate—psoriasis	8.96e-05	8.99e-05	CcSEcCtD
Pramipexole—Dizziness—Hydrocortisone—psoriasis	8.92e-05	8.95e-05	CcSEcCtD
Pramipexole—Convulsion—Methotrexate—psoriasis	8.9e-05	8.93e-05	CcSEcCtD
Pramipexole—Dyspepsia—Prednisone—psoriasis	8.83e-05	8.86e-05	CcSEcCtD
Pramipexole—Nausea—Mycophenolate mofetil—psoriasis	8.79e-05	8.82e-05	CcSEcCtD
Pramipexole—Chest pain—Methotrexate—psoriasis	8.74e-05	8.77e-05	CcSEcCtD
Pramipexole—Arthralgia—Methotrexate—psoriasis	8.74e-05	8.77e-05	CcSEcCtD
Pramipexole—Myalgia—Methotrexate—psoriasis	8.74e-05	8.77e-05	CcSEcCtD
Pramipexole—Decreased appetite—Prednisone—psoriasis	8.72e-05	8.75e-05	CcSEcCtD
Pramipexole—Rash—Prednisolone—psoriasis	8.7e-05	8.73e-05	CcSEcCtD
Pramipexole—Dermatitis—Prednisolone—psoriasis	8.7e-05	8.72e-05	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	8.68e-05	8.71e-05	CcSEcCtD
Pramipexole—Fatigue—Prednisone—psoriasis	8.65e-05	8.68e-05	CcSEcCtD
Pramipexole—Headache—Prednisolone—psoriasis	8.65e-05	8.68e-05	CcSEcCtD
Pramipexole—Discomfort—Methotrexate—psoriasis	8.64e-05	8.67e-05	CcSEcCtD
Pramipexole—Constipation—Prednisone—psoriasis	8.58e-05	8.61e-05	CcSEcCtD
Pramipexole—Vomiting—Hydrocortisone—psoriasis	8.57e-05	8.6e-05	CcSEcCtD
Pramipexole—Rash—Hydrocortisone—psoriasis	8.5e-05	8.53e-05	CcSEcCtD
Pramipexole—Dermatitis—Hydrocortisone—psoriasis	8.49e-05	8.52e-05	CcSEcCtD
Pramipexole—Confusional state—Methotrexate—psoriasis	8.45e-05	8.48e-05	CcSEcCtD
Pramipexole—Headache—Hydrocortisone—psoriasis	8.45e-05	8.47e-05	CcSEcCtD
Pramipexole—Dizziness—Triamcinolone—psoriasis	8.39e-05	8.42e-05	CcSEcCtD
Pramipexole—Infection—Methotrexate—psoriasis	8.33e-05	8.36e-05	CcSEcCtD
Pramipexole—Feeling abnormal—Prednisone—psoriasis	8.27e-05	8.29e-05	CcSEcCtD
Pramipexole—Asthenia—Dexamethasone—psoriasis	8.26e-05	8.29e-05	CcSEcCtD
Pramipexole—Asthenia—Betamethasone—psoriasis	8.26e-05	8.29e-05	CcSEcCtD
Pramipexole—Nervous system disorder—Methotrexate—psoriasis	8.22e-05	8.25e-05	CcSEcCtD
Pramipexole—Thrombocytopenia—Methotrexate—psoriasis	8.21e-05	8.24e-05	CcSEcCtD
Pramipexole—Gastrointestinal pain—Prednisone—psoriasis	8.2e-05	8.23e-05	CcSEcCtD
Pramipexole—Nausea—Prednisolone—psoriasis	8.2e-05	8.23e-05	CcSEcCtD
Pramipexole—Pruritus—Dexamethasone—psoriasis	8.15e-05	8.18e-05	CcSEcCtD
Pramipexole—Pruritus—Betamethasone—psoriasis	8.15e-05	8.18e-05	CcSEcCtD
Pramipexole—Skin disorder—Methotrexate—psoriasis	8.14e-05	8.17e-05	CcSEcCtD
Pramipexole—Hyperhidrosis—Methotrexate—psoriasis	8.1e-05	8.13e-05	CcSEcCtD
Pramipexole—Vomiting—Triamcinolone—psoriasis	8.07e-05	8.1e-05	CcSEcCtD
Pramipexole—Nausea—Hydrocortisone—psoriasis	8.01e-05	8.03e-05	CcSEcCtD
Pramipexole—Rash—Triamcinolone—psoriasis	8e-05	8.03e-05	CcSEcCtD
Pramipexole—Dermatitis—Triamcinolone—psoriasis	8e-05	8.02e-05	CcSEcCtD
Pramipexole—Anorexia—Methotrexate—psoriasis	7.99e-05	8.02e-05	CcSEcCtD
Pramipexole—Urticaria—Prednisone—psoriasis	7.97e-05	8e-05	CcSEcCtD
Pramipexole—Headache—Triamcinolone—psoriasis	7.95e-05	7.98e-05	CcSEcCtD
Pramipexole—Abdominal pain—Prednisone—psoriasis	7.93e-05	7.96e-05	CcSEcCtD
Pramipexole—Body temperature increased—Prednisone—psoriasis	7.93e-05	7.96e-05	CcSEcCtD
Pramipexole—Diarrhoea—Dexamethasone—psoriasis	7.88e-05	7.91e-05	CcSEcCtD
Pramipexole—Diarrhoea—Betamethasone—psoriasis	7.88e-05	7.91e-05	CcSEcCtD
Pramipexole—Hypotension—Methotrexate—psoriasis	7.83e-05	7.86e-05	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Methotrexate—psoriasis	7.64e-05	7.66e-05	CcSEcCtD
Pramipexole—Dizziness—Dexamethasone—psoriasis	7.62e-05	7.64e-05	CcSEcCtD
Pramipexole—Dizziness—Betamethasone—psoriasis	7.62e-05	7.64e-05	CcSEcCtD
Pramipexole—Insomnia—Methotrexate—psoriasis	7.58e-05	7.61e-05	CcSEcCtD
Pramipexole—Nausea—Triamcinolone—psoriasis	7.54e-05	7.57e-05	CcSEcCtD
Pramipexole—Paraesthesia—Methotrexate—psoriasis	7.53e-05	7.55e-05	CcSEcCtD
Pramipexole—Dyspnoea—Methotrexate—psoriasis	7.47e-05	7.5e-05	CcSEcCtD
Pramipexole—Somnolence—Methotrexate—psoriasis	7.45e-05	7.48e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Prednisone—psoriasis	7.39e-05	7.42e-05	CcSEcCtD
Pramipexole—Dyspepsia—Methotrexate—psoriasis	7.38e-05	7.4e-05	CcSEcCtD
Pramipexole—Vomiting—Dexamethasone—psoriasis	7.32e-05	7.35e-05	CcSEcCtD
Pramipexole—Vomiting—Betamethasone—psoriasis	7.32e-05	7.35e-05	CcSEcCtD
Pramipexole—Decreased appetite—Methotrexate—psoriasis	7.29e-05	7.31e-05	CcSEcCtD
Pramipexole—Rash—Betamethasone—psoriasis	7.26e-05	7.29e-05	CcSEcCtD
Pramipexole—Rash—Dexamethasone—psoriasis	7.26e-05	7.29e-05	CcSEcCtD
Pramipexole—Dermatitis—Betamethasone—psoriasis	7.26e-05	7.28e-05	CcSEcCtD
Pramipexole—Dermatitis—Dexamethasone—psoriasis	7.26e-05	7.28e-05	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Methotrexate—psoriasis	7.24e-05	7.26e-05	CcSEcCtD
Pramipexole—Fatigue—Methotrexate—psoriasis	7.23e-05	7.25e-05	CcSEcCtD
Pramipexole—Headache—Betamethasone—psoriasis	7.22e-05	7.24e-05	CcSEcCtD
Pramipexole—Headache—Dexamethasone—psoriasis	7.22e-05	7.24e-05	CcSEcCtD
Pramipexole—Asthenia—Prednisone—psoriasis	7.2e-05	7.22e-05	CcSEcCtD
Pramipexole—Pain—Methotrexate—psoriasis	7.17e-05	7.19e-05	CcSEcCtD
Pramipexole—Pruritus—Prednisone—psoriasis	7.1e-05	7.12e-05	CcSEcCtD
Pramipexole—Feeling abnormal—Methotrexate—psoriasis	6.91e-05	6.93e-05	CcSEcCtD
Pramipexole—Diarrhoea—Prednisone—psoriasis	6.86e-05	6.89e-05	CcSEcCtD
Pramipexole—Gastrointestinal pain—Methotrexate—psoriasis	6.86e-05	6.88e-05	CcSEcCtD
Pramipexole—Nausea—Betamethasone—psoriasis	6.84e-05	6.86e-05	CcSEcCtD
Pramipexole—Nausea—Dexamethasone—psoriasis	6.84e-05	6.86e-05	CcSEcCtD
Pramipexole—Urticaria—Methotrexate—psoriasis	6.66e-05	6.68e-05	CcSEcCtD
Pramipexole—Dizziness—Prednisone—psoriasis	6.63e-05	6.66e-05	CcSEcCtD
Pramipexole—Abdominal pain—Methotrexate—psoriasis	6.63e-05	6.65e-05	CcSEcCtD
Pramipexole—Body temperature increased—Methotrexate—psoriasis	6.63e-05	6.65e-05	CcSEcCtD
Pramipexole—Vomiting—Prednisone—psoriasis	6.38e-05	6.4e-05	CcSEcCtD
Pramipexole—Rash—Prednisone—psoriasis	6.32e-05	6.35e-05	CcSEcCtD
Pramipexole—Dermatitis—Prednisone—psoriasis	6.32e-05	6.34e-05	CcSEcCtD
Pramipexole—Headache—Prednisone—psoriasis	6.28e-05	6.31e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Methotrexate—psoriasis	6.18e-05	6.2e-05	CcSEcCtD
Pramipexole—Asthenia—Methotrexate—psoriasis	6.01e-05	6.03e-05	CcSEcCtD
Pramipexole—Nausea—Prednisone—psoriasis	5.96e-05	5.98e-05	CcSEcCtD
Pramipexole—Pruritus—Methotrexate—psoriasis	5.93e-05	5.95e-05	CcSEcCtD
Pramipexole—Diarrhoea—Methotrexate—psoriasis	5.74e-05	5.76e-05	CcSEcCtD
Pramipexole—Dizziness—Methotrexate—psoriasis	5.54e-05	5.56e-05	CcSEcCtD
Pramipexole—Vomiting—Methotrexate—psoriasis	5.33e-05	5.35e-05	CcSEcCtD
Pramipexole—Rash—Methotrexate—psoriasis	5.29e-05	5.3e-05	CcSEcCtD
Pramipexole—Dermatitis—Methotrexate—psoriasis	5.28e-05	5.3e-05	CcSEcCtD
Pramipexole—Headache—Methotrexate—psoriasis	5.25e-05	5.27e-05	CcSEcCtD
Pramipexole—Nausea—Methotrexate—psoriasis	4.98e-05	5e-05	CcSEcCtD
Pramipexole—DRD2—Signaling Pathways—CCL20—psoriasis	2.65e-06	0.000789	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—NOS2—psoriasis	2.65e-06	0.000789	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCL20—psoriasis	2.6e-06	0.000776	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR ligand binding—CXCL8—psoriasis	2.6e-06	0.000774	CbGpPWpGaD
Pramipexole—DRD2—Circadian rythm related genes—IL6—psoriasis	2.48e-06	0.000739	CbGpPWpGaD
Pramipexole—DRD5—Signaling by GPCR—CXCL8—psoriasis	2.41e-06	0.000719	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—CARM1—psoriasis	2.41e-06	0.000718	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCL20—psoriasis	2.37e-06	0.000706	CbGpPWpGaD
Pramipexole—DRD2—GPCR ligand binding—CXCL8—psoriasis	2.36e-06	0.000703	CbGpPWpGaD
Pramipexole—HTR2A—GPCR ligand binding—CXCL8—psoriasis	2.32e-06	0.000691	CbGpPWpGaD
Pramipexole—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.31e-06	0.000689	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—SOCS1—psoriasis	2.22e-06	0.000663	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—SOCS1—psoriasis	2.18e-06	0.000649	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—SOCS1—psoriasis	2.14e-06	0.000639	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—LEP—psoriasis	2.14e-06	0.000639	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—APOE—psoriasis	2.14e-06	0.000639	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—TYK2—psoriasis	2.12e-06	0.000632	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR ligand binding—CXCL8—psoriasis	2.11e-06	0.000629	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—TYK2—psoriasis	2.08e-06	0.000619	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—SOCS1—psoriasis	2.05e-06	0.00061	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—TYK2—psoriasis	2.04e-06	0.000609	CbGpPWpGaD
Pramipexole—HTR1D—GPCR downstream signaling—CXCL8—psoriasis	2.03e-06	0.000606	CbGpPWpGaD
Pramipexole—ADRA2B—Hemostasis—VEGFA—psoriasis	2.02e-06	0.000602	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—NFKBIA—psoriasis	2e-06	0.000595	CbGpPWpGaD
Pramipexole—HTR1B—GPCR downstream signaling—CXCL8—psoriasis	1.99e-06	0.000594	CbGpPWpGaD
Pramipexole—DRD4—GPCR downstream signaling—CXCL8—psoriasis	1.96e-06	0.000584	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—TYK2—psoriasis	1.95e-06	0.000582	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—SOCS1—psoriasis	1.93e-06	0.000575	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—SOCS1—psoriasis	1.9e-06	0.000568	CbGpPWpGaD
Pramipexole—ADRA2C—Hemostasis—VEGFA—psoriasis	1.89e-06	0.000562	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—CAT—psoriasis	1.87e-06	0.000559	CbGpPWpGaD
Pramipexole—HTR2B—GPCR downstream signaling—CXCL8—psoriasis	1.87e-06	0.000558	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—CXCL8—psoriasis	1.85e-06	0.000551	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—TYK2—psoriasis	1.84e-06	0.000548	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—CAT—psoriasis	1.82e-06	0.000544	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—TYK2—psoriasis	1.82e-06	0.000541	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—CXCL8—psoriasis	1.81e-06	0.000539	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—CXCL8—psoriasis	1.78e-06	0.00053	CbGpPWpGaD
Pramipexole—DRD1—GPCR downstream signaling—CXCL8—psoriasis	1.76e-06	0.000526	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—CAT—psoriasis	1.75e-06	0.000521	CbGpPWpGaD
Pramipexole—DRD3—GPCR downstream signaling—CXCL8—psoriasis	1.74e-06	0.000519	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—SOCS1—psoriasis	1.72e-06	0.000512	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—CXCL8—psoriasis	1.7e-06	0.000506	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—SOCS1—psoriasis	1.66e-06	0.000495	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—SOCS1—psoriasis	1.65e-06	0.000492	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—LEP—psoriasis	1.64e-06	0.000489	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—APOE—psoriasis	1.64e-06	0.000489	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—TYK2—psoriasis	1.64e-06	0.000489	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—TYK2—psoriasis	1.64e-06	0.000488	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—APOE—psoriasis	1.61e-06	0.000479	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—LEP—psoriasis	1.61e-06	0.000479	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—SOCS1—psoriasis	1.61e-06	0.000479	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—CXCL8—psoriasis	1.6e-06	0.000478	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—TYK2—psoriasis	1.58e-06	0.000472	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—APOE—psoriasis	1.58e-06	0.000472	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—LEP—psoriasis	1.58e-06	0.000472	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—CXCL8—psoriasis	1.58e-06	0.000471	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—TYK2—psoriasis	1.57e-06	0.000469	CbGpPWpGaD
Pramipexole—ADRA2B—GPCR downstream signaling—CXCL8—psoriasis	1.57e-06	0.000468	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—VEGFA—psoriasis	1.53e-06	0.000457	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—TYK2—psoriasis	1.53e-06	0.000456	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—NFKBIA—psoriasis	1.53e-06	0.000456	CbGpPWpGaD
Pramipexole—ADRA2B—Hemostasis—TP53—psoriasis	1.53e-06	0.000455	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—CXCL8—psoriasis	1.52e-06	0.000452	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—LEP—psoriasis	1.51e-06	0.00045	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—APOE—psoriasis	1.51e-06	0.00045	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	1.51e-06	0.00045	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—NFKBIA—psoriasis	1.5e-06	0.000447	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—CAT—psoriasis	1.48e-06	0.000442	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—NFKBIA—psoriasis	1.47e-06	0.000439	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—CXCL8—psoriasis	1.47e-06	0.000438	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—APOE—psoriasis	1.46e-06	0.000434	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SOCS1—psoriasis	1.46e-06	0.000434	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SOCS1—psoriasis	1.43e-06	0.000427	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—CXCL8—psoriasis	1.43e-06	0.000425	CbGpPWpGaD
Pramipexole—ADRA2C—Hemostasis—TP53—psoriasis	1.43e-06	0.000425	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—CXCL8—psoriasis	1.42e-06	0.000425	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—APOE—psoriasis	1.42e-06	0.000424	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—LEP—psoriasis	1.42e-06	0.000424	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—APOE—psoriasis	1.42e-06	0.000422	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—NFKBIA—psoriasis	1.41e-06	0.000419	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—LEP—psoriasis	1.4e-06	0.000419	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—APOE—psoriasis	1.4e-06	0.000419	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—TYK2—psoriasis	1.39e-06	0.000414	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—CXCL8—psoriasis	1.38e-06	0.000411	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—CXCL8—psoriasis	1.37e-06	0.000409	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—TYK2—psoriasis	1.37e-06	0.000407	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—APOE—psoriasis	1.36e-06	0.000405	CbGpPWpGaD
Pramipexole—DRD5—Signaling by GPCR—IL6—psoriasis	1.35e-06	0.000404	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—CXCL8—psoriasis	1.33e-06	0.000397	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—CXCL8—psoriasis	1.33e-06	0.000397	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—NFKBIA—psoriasis	1.33e-06	0.000396	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—JUN—psoriasis	1.32e-06	0.000395	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	1.31e-06	0.000391	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—NFKBIA—psoriasis	1.31e-06	0.00039	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SOCS1—psoriasis	1.3e-06	0.000389	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—NFKB1—psoriasis	1.27e-06	0.00038	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PPARG—psoriasis	1.27e-06	0.000378	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—LEP—psoriasis	1.27e-06	0.000378	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—APOE—psoriasis	1.27e-06	0.000378	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TYK2—psoriasis	1.25e-06	0.000374	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—TYK2—psoriasis	1.24e-06	0.000371	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PPARG—psoriasis	1.23e-06	0.000368	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TYK2—psoriasis	1.23e-06	0.000366	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—APOE—psoriasis	1.22e-06	0.000365	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—LEP—psoriasis	1.22e-06	0.000365	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—LEP—psoriasis	1.22e-06	0.000363	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—APOE—psoriasis	1.22e-06	0.000363	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—CXCL8—psoriasis	1.21e-06	0.000361	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TYK2—psoriasis	1.21e-06	0.00036	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—CXCL8—psoriasis	1.19e-06	0.000355	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—CXCL8—psoriasis	1.19e-06	0.000355	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—LEP—psoriasis	1.18e-06	0.000353	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—APOE—psoriasis	1.18e-06	0.000353	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PPARG—psoriasis	1.18e-06	0.000353	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NFKBIA—psoriasis	1.18e-06	0.000352	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—TP53—psoriasis	1.16e-06	0.000345	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—VEGFA—psoriasis	1.16e-06	0.000345	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TYK2—psoriasis	1.15e-06	0.000344	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—APOE—psoriasis	1.15e-06	0.000343	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—STAT3—psoriasis	1.15e-06	0.000341	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NFKBIA—psoriasis	1.14e-06	0.00034	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NFKBIA—psoriasis	1.14e-06	0.000338	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NFKBIA—psoriasis	1.1e-06	0.000329	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—CXCL8—psoriasis	1.09e-06	0.000325	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TYK2—psoriasis	1.09e-06	0.000324	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	1.08e-06	0.000323	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—LEP—psoriasis	1.07e-06	0.00032	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—APOE—psoriasis	1.07e-06	0.00032	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TYK2—psoriasis	1.07e-06	0.00032	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CXCL8—psoriasis	1.07e-06	0.000318	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—APOE—psoriasis	1.06e-06	0.000315	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—LEP—psoriasis	1.06e-06	0.000315	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CXCL8—psoriasis	1.05e-06	0.000313	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—IL6—psoriasis	1.04e-06	0.000309	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—IL6—psoriasis	1.02e-06	0.000303	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—JUN—psoriasis	1.01e-06	0.000302	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CXCL8—psoriasis	1e-06	0.000299	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PPARG—psoriasis	1e-06	0.000299	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NFKBIA—psoriasis	1e-06	0.000299	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—IL6—psoriasis	9.99e-07	0.000298	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—JUN—psoriasis	9.93e-07	0.000296	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NFKBIA—psoriasis	9.86e-07	0.000294	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—JUN—psoriasis	9.77e-07	0.000291	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—NFKB1—psoriasis	9.76e-07	0.000291	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TYK2—psoriasis	9.68e-07	0.000289	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—LEP—psoriasis	9.62e-07	0.000287	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—APOE—psoriasis	9.62e-07	0.000287	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—NFKB1—psoriasis	9.56e-07	0.000285	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—IL6—psoriasis	9.54e-07	0.000284	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CXCL8—psoriasis	9.46e-07	0.000282	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—NFKB1—psoriasis	9.41e-07	0.00028	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TYK2—psoriasis	9.34e-07	0.000279	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CXCL8—psoriasis	9.34e-07	0.000278	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—JUN—psoriasis	9.33e-07	0.000278	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TYK2—psoriasis	9.3e-07	0.000277	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TYK2—psoriasis	9.04e-07	0.00027	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—IL6—psoriasis	9e-07	0.000268	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—NFKB1—psoriasis	8.98e-07	0.000268	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	8.97e-07	0.000267	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—IL6—psoriasis	8.88e-07	0.000265	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—VEGFA—psoriasis	8.86e-07	0.000264	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—JUN—psoriasis	8.8e-07	0.000262	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—STAT3—psoriasis	8.77e-07	0.000262	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—TP53—psoriasis	8.74e-07	0.000261	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—JUN—psoriasis	8.68e-07	0.000259	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—VEGFA—psoriasis	8.67e-07	0.000259	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—STAT3—psoriasis	8.59e-07	0.000256	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—VEGFA—psoriasis	8.54e-07	0.000254	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—NFKB1—psoriasis	8.47e-07	0.000252	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—STAT3—psoriasis	8.45e-07	0.000252	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CXCL8—psoriasis	8.43e-07	0.000251	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—NFKB1—psoriasis	8.35e-07	0.000249	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TYK2—psoriasis	8.2e-07	0.000245	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—VEGFA—psoriasis	8.15e-07	0.000243	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CXCL8—psoriasis	8.14e-07	0.000243	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CXCL8—psoriasis	8.09e-07	0.000241	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TYK2—psoriasis	8.07e-07	0.000241	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—STAT3—psoriasis	8.07e-07	0.000241	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—IL6—psoriasis	8.01e-07	0.000239	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—IL6—psoriasis	8e-07	0.000238	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CXCL8—psoriasis	7.87e-07	0.000235	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—JUN—psoriasis	7.84e-07	0.000234	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL6—psoriasis	7.74e-07	0.000231	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL6—psoriasis	7.7e-07	0.000229	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—VEGFA—psoriasis	7.68e-07	0.000229	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—STAT3—psoriasis	7.61e-07	0.000227	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—VEGFA—psoriasis	7.58e-07	0.000226	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—JUN—psoriasis	7.56e-07	0.000226	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NFKB1—psoriasis	7.54e-07	0.000225	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—JUN—psoriasis	7.53e-07	0.000224	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—STAT3—psoriasis	7.51e-07	0.000224	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL6—psoriasis	7.49e-07	0.000223	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TYK2—psoriasis	7.34e-07	0.000219	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—JUN—psoriasis	7.32e-07	0.000218	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NFKB1—psoriasis	7.28e-07	0.000217	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NFKB1—psoriasis	7.24e-07	0.000216	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CXCL8—psoriasis	7.14e-07	0.000213	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NFKB1—psoriasis	7.05e-07	0.00021	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CXCL8—psoriasis	7.03e-07	0.00021	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—VEGFA—psoriasis	6.85e-07	0.000204	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL6—psoriasis	6.79e-07	0.000203	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—STAT3—psoriasis	6.78e-07	0.000202	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TP53—psoriasis	6.69e-07	0.0002	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL6—psoriasis	6.68e-07	0.000199	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—JUN—psoriasis	6.64e-07	0.000198	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—VEGFA—psoriasis	6.61e-07	0.000197	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—VEGFA—psoriasis	6.57e-07	0.000196	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TP53—psoriasis	6.55e-07	0.000195	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—STAT3—psoriasis	6.54e-07	0.000195	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—JUN—psoriasis	6.53e-07	0.000195	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—STAT3—psoriasis	6.51e-07	0.000194	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TP53—psoriasis	6.45e-07	0.000192	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CXCL8—psoriasis	6.39e-07	0.000191	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—VEGFA—psoriasis	6.39e-07	0.000191	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NFKB1—psoriasis	6.39e-07	0.000191	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—STAT3—psoriasis	6.33e-07	0.000189	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NFKB1—psoriasis	6.29e-07	0.000188	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TP53—psoriasis	6.16e-07	0.000184	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL6—psoriasis	6.13e-07	0.000183	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL6—psoriasis	6.08e-07	0.000181	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL6—psoriasis	6e-07	0.000179	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—JUN—psoriasis	5.95e-07	0.000177	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL6—psoriasis	5.9e-07	0.000176	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TP53—psoriasis	5.81e-07	0.000173	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—VEGFA—psoriasis	5.8e-07	0.000173	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—STAT3—psoriasis	5.74e-07	0.000171	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TP53—psoriasis	5.73e-07	0.000171	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NFKB1—psoriasis	5.72e-07	0.000171	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—VEGFA—psoriasis	5.71e-07	0.00017	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—STAT3—psoriasis	5.65e-07	0.000169	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL6—psoriasis	5.64e-07	0.000168	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL6—psoriasis	5.31e-07	0.000158	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL6—psoriasis	5.24e-07	0.000156	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—VEGFA—psoriasis	5.19e-07	0.000155	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TP53—psoriasis	5.17e-07	0.000154	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—STAT3—psoriasis	5.14e-07	0.000153	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TP53—psoriasis	4.99e-07	0.000149	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TP53—psoriasis	4.97e-07	0.000148	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TP53—psoriasis	4.83e-07	0.000144	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL6—psoriasis	4.73e-07	0.000141	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL6—psoriasis	4.57e-07	0.000136	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL6—psoriasis	4.55e-07	0.000136	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL6—psoriasis	4.42e-07	0.000132	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TP53—psoriasis	4.38e-07	0.000131	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TP53—psoriasis	4.31e-07	0.000129	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL6—psoriasis	4.01e-07	0.00012	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL6—psoriasis	3.95e-07	0.000118	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TP53—psoriasis	3.92e-07	0.000117	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL6—psoriasis	3.59e-07	0.000107	CbGpPWpGaD
